Yet the market opportunity is substantial. During the latest quarter, the revenues jumped by 41% to $34.1 million. This not only has provided for next-generation treatments but has allowed for a rich source of data collection.Īs for the growth rate, it has been robust. These systems also interact with each other, such as with data integration.Īnother key to the strategy is a nationwide network of 34 patient care centers. There is LinkCare for continuous care for disease, LinkData for AI-based curation based on longitudinal medical data and LinkSolutions for helping life science companies accelerate drug development. The company has three different offerings. According to research from Frost & Sullien, LinkDoc has the largest dataset of China’s oncology cohorts and has built the most extensive digital infrastructure for precision medicine. Perhaps the most important is its trove of valuable data. Nevertheless, LinkDoc has some major advantages. After all, companies like IBM ( IBM) have tried to do the same thing but have faced major challenges. The core vision of LinkDoc is to use precision medicine and personalized care to essentially uncover the story of every patient. So then, let’s take a deeper look at the company as well as what we may see about Chinese IPOs.

The fact is that there are major regulatory shifts in China. Of course, this was not necessarily about the company. (See IPO Calendar on TipRanks) It looked like the deal had traction with investors, with the valuation at about $1.5 billion.īut unfortunately, LinkDoc suspended the offering. LinkDoc Technology, which is a China-based company that leverages sophisticated data technologies for oncology patients, was expected to pull off its IPO last week.

Linkdoc ipo